Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4- dichlorophenoxy]quinoline succinate

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2130-2137

  Nanayakkara, N P Dhammika ^a,f   Ager Jr , Arba L ^c   Bartlett, Marilyn S ^d   Yardley, Vanessa ^e   Croft, Simon L ^e   Khan, Ikhlas A ^a,b   McChesney, James D ^a,b,g   Walker, Larry A ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF MISSISSIPPI   (United States)

^g Tapestry Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [(4 AMINO 1 METHYLBUTYL)AMINO] 6 METHOXY 4 METHYL 5 (3,4 DICHLOROPHENOXY)QUINOLINE SUCCINATE; 8 AMINOQUINOLINE 8 [(4 AMINO 1 METHYLBUTYL)AMINO] 6 METHOXY 4 METHYL 5 (3,4 DICHLOROPHENOXY)QUINOLINE SUCCINATE; 8 AMINOQUINOLINE DERIVATIVE; ANTIPARASITIC AGENT; METHEMOGLOBIN; NPC 1161A; NPC 1161B; NPC 1161C; PRIMAQUINE; SITAMAQUINE; TAFENOQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CHEMICAL REACTION; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; ENANTIOMER; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALARIA; MALE; METHEMOGLOBINEMIA; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RACEMIC MIXTURE;

AMINOQUINOLINES; ANIMALS; ANTIFUNGAL AGENTS; ANTIPROTOZOAL AGENTS; DOGS; FEMALE; HEMOLYSIS; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MALARIA; MALE; METHEMOGLOBINEMIA; MICE; MICE, INBRED BALB C; PLASMODIUM BERGHEI; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44449113132     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00645-07     Document Type: Article

References (49)

1. Agarwal, S., U. R. Gupta, R. C. Gupta, N. Anand, and S. S. Agarwal. 1988. Susceptibility of glucose-6-phosphate dehydrogenase-deficient red cells to primaquine enantiomers and two putative metabolites. I. Effect on reduced glutathione, methemoglobin content and release of hemoglobin. Biochem. Pharmacol. 37:4605-4609.
2. Baird, J. K., and S. L. Hoffman. 2004. Primaquine therapy for malaria. Clin. Infect. Dis. 39:1336-1345.
3. Baird, J. K., G. J. McCormick, and C. J. Canfield. 1986. Effects of nine synthetic putative metabolites of primaquine on activity of the hexose monophosphate shunt in intact human red blood cells in vitro. Biochem. Pharmacol. 35:1099-1106.
4. Baker, J. K., and J. D. McChesney. 1988. Differential metabolism of the enantiomers of primaquine. J. Pharm. Sci. 77:380-382.
5. Bartlett, M. S., S. F. Queener, R. R. Tidwell, W. K. Milhous, J. D. Berman, W. Y. Ellis, and J. W. Smith. 1991. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob. Agents Chemother. 35:277-282.
6. Bartlett, M. S., S. F. Queener, M. M. Durkin, M. M. Shaw, and J. W. Smith. 1992. Inoculated mouse model of Pneumocystis carinii infection. Diagn. Microbiol. Infect. Dis. 15:129-134.
7. Bartlett, M. S., S. F. Queener, M. M. Shaw, P. J. Durant, C. H. Lee, and J. W. Smith. 1997. In vitro and in vivo models of Pneumocystis carinii. J. Eukaryot. Microbiol. 44:51S.
8. Bates, M. D., S. R. Meshnick, C. I. Sigler, P. Leland, and M. R. Hollingdale. 1990. In vitro effects of primaquine and primaquine metabolites on exoerythrocytic stages of Plasmodium berghei. Am. J. Trop. Med. Hyg. 42:532-537.
9. Becker, K., L. Tilley, J. L. Vennerstrom, D. Roberts, S. Rogerson, and H. Ginsburg. 2004. Oxidative stress in malaria parasite-infected erythrocytes: host-parasite interactions. Int. J. Parasitol. 34:163-189.
10. Black, J. R., J. Feinberg, R. L. Murphy, R. J. Fass, J. Carey, and F. R. Sattler. 1991. Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 10:204-207.
11. Black, J. R., J. Feinberg, R. L. Murphy, R. J. Fass, D. Finkelstein, B. Akil, S. Safrin, J. T. Carey, J. Stansell, and J. F. Plouffe. 1994. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. Clin. Infect. Dis. 18:905-913.
12. Bolchoz, L. J. C., A. K. Gelasco, D. J. Jollow, and D. C. McMillan. 2002. Primaquine-induced hemolytic anemia: formation of free radicals in rat erythrocytes exposed to 6-methoxy-8-hydroxylaminoquinoline. J. Pharmacol. Exp. Ther. 303:1121-1129.
13. Bowman, Z. S., J. E. Oatis, Jr., J. L. Whelan, D. J. Jollow, and D. C. McMillan. 2004. Primaquine-induced hemolytic anemia: susceptibility of normal versus glutathione-depleted rat erythrocytes to 5-hydroxyprimaquine. J. Pharmacol. Exp. Ther. 309:79-85.
14. Brossi, A., P. Millet, I. Landau, M. E. Bembenek, and C. W. Abell. 1987. Antimalarial activity and inhibition of monoamine oxidases A and B by exo-erythrocytic antimalarials. Optical isomers of primaquine, N-acylated congeners, primaquine metabolites and 5-phenoxy-substituted analogs. FEBS Lett. 214:291-294.
15. Campbell, K. N., A. H. Sommers, J. H. Kerwin, and B. K. Campbell. 1946. Quinoline series. III. Preparation of some 8-(ω- alkylaminoalkylamino)-quinolines. J. Am. Chem. Soc. 68:1556-1559.
16. Cohen, R. J., J. R. Sachs, D. J. Wicker, and M. E. Conrad. 1968. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N. Engl. J. Med. 279:1127-1131.
17. Dietze, R., S. F. G. Carvalho, L. C. Valli, J. Berman, T. Brewer, W. Milhous, J. Sanchez, B. Schuster, and M. Grogl. 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. 65:685-689.
18. Elsohly, M. A., W. Gul, S. Feng, N. P. D. Nanayakkara, A. M. Clark, S. Khan, F. B. Cogswell, and L. A. Walker. 2006. GC-MS analysis of the 8-aminoquinoline antimalarial [NPC1161] and its carboxy metabolite in plasma and red blood cells of primates. Chromatographia 64:199-205.
19. Fletcher, K. A., P. F. Barton, and J. A. Kelly. 1988. Studies on the mechanisms of oxidation in the erythrocyte by metabolites of primaquine. Biochem. Pharmacol. 37:2683-2690.
20. Garces, J. L., J. Arrizabalaga, J. A. Iribarren, F. Rodriguez, C. Garde, and A. Garcia. 1994. Clindamycin-primaquine in the treatment of Pneumocystis carinii pneumonia. Enferm. Infecc. Microbiol. Clin. 12:154-157.
21. Jha, T. K., S. Sundar, C. P. Thakur, J. M. Felton, A. J. Sabin, and J. Horton. 2005. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg. 73:1005-1011.
22. Kantor, G. S. 1992. Primaquine-induced methemoglobinemia during treatment of Pneumocystis carinii pneumonia. N. Engl. J. Med. 327:1461.
23. Kay, R., and R. E. DuBois. 1990. Clindamycin/ primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. South. Med. J. 83:403-404.
24. Kinnamon, K. E., B. T. Poon, W. L. Hanson, and V. B. Waits. 1996. Primaquine analogs that are potent anti-Trypanosoma cruzi agents in a mouse model. Ann. Trop. Med. Parasitol. 90:467-474.
25. Kinnamon, K. E., E. A. Steck, P. S. Loizeaux, W. L. Hanson, W. L. Chapman, Jr., and V. B. Waits. 1978. The antileishmanial activity of lepidines. Am. J. Trop. Med. Hyg. 27:751-757.
26. LaMontagne, M. P., P. Blumbergs, and R. E. Strube. 1982. Antimalarials. 14. 5-(Aryloxy)-4-methylprimaquine analogs. A highly effective series of blood and tissue schizonticidal agents. J. Med. Chem. 25:1094-1097.
27. Link, C. M., A. D. Theoharides, J. C. Anders, H. Chung, and C. J. Canfield. 1985. Structure-activity relationships of putative primaquine metabolites causing methemoglobin formation in canine hemolyzates. Toxicol. Appl. Pharmacol. 81:192-202.
28. McCabe, R. E. 1988. Primaquine is lethal for intracellular but not extracellular Trypanosoma cruzi. J. Parasitol. 74:748-753.
29. McChesney, J. D., N. P. D. Nanayakkara, M. Bartlett, and A. L. Ager. April 2002. 8-Aminoquinolines. U.S. patent 6,376,511.
30. Nicholl, D. D., G. Edwards, S. A. Ward, M. L. Orme, and A. M. Breckenridge. 1987. The disposition of primaquine in the isolated perfused rat liver. Stereoselective formation of the carboxylic acid metabolite. Biochem. Pharmacol. 36:3365-3369.
31. Nodiff, E. A., S. Chatterjee, and H. A. Musallam. 1991. Antimalarial activity of the 8-aminoquinolines. Prog. Med. Chem. 28:1-40.
32. Queener, S. F., M. S. Bartlett, M. Nasr, and J. W. Smith. 1993. 8-Amino-quinolines effective against Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. 37:2166-2172.
33. Queener, S. F., M. S. Bartlett, J. D. Richardson, M. M. Durkin, M. A. Jay, and J. W. Smith. 1988. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. 32:807-813.
34. Queener, S. F., R. A. Deen, M. S. Bartlett, W. K. Milhous, J. D. Berman, W. Y. Ellis, and J. W. Smith. 1992. Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis carinii pneumonia in rats. J. Infect. Dis. 165:764-768.
35. Ramharter, M., H. Noedl, K. Thimasarn, G. Wiedermann, G. Wernsdorfer, and W. H. Wernsdorfer. 2002. In vitro activity of tafenoquine alone and in combination with artemisinin against Plasmodium falciparum. Am. J. Trop. Med. Hyg. 67:39-43.
36. Schmidt, L. H., S. Alexander, L. Allen, and J. Rasco. 1977. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob. Agents Chemother. 12:51-60.
37. Sherwood, J. A., G. S. Gachihi, R. K. Muigai, D. R. Skillman, M. Mugo, J. R. Rashid, K. M. Wasunna, J. B. Were, S. K. Kasili, and J. M. Mbugua. 1994. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 19:1034-1039.
38. Srivastava, S., A. S. Alhomida, N. J. Siddiqi, S. K. Puri, and V. C. Pandey. 2002. Methemoglobin reductase activity and in vitro sensitivity towards oxidant induced methemoglobinemia in Swiss mice and beagle dogs erythrocytes. Mol. Cell. Biochem. 232:81-85.
39. Stjaernkvist, P. 1993. Biodegradable microspheres: XIV. Effect of microparticle-bound primaquine on Leishmania donovani in mice. Int. J. Pharm. 96:23-32.
40. Tarlov, A. R., G. L. Brewer, P. E. Carson, and A. S. Alving. 1962. Primaquine sensitivity. Arch. Intern. Med. 109:209-234.
41. Tekwani, B. L., and L. A. Walker. 2006. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis. 19:623-631.
42. Thompson, P. E., B. Olszewski, A. Bayles, and J. A. Waitz. 1967. Relations among antimalarial drugs: results of studies with cycloquanil-, sulfone-, or chloroquine-resistant Plasmodium berghei in mice. Am. J. Trop. Med. Hyg. 16:133-145.
43. Toma, E. 1991. Clindamycin/primaquine for treatment of Pneumocystis carinii pneumonia in AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 10:210-213.
44. Toma, E., S. Fournier, M. Dumont, P Bolduc, and H. Deschamps. 1993. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin. Infect. Dis. 17:178-184.
45. Toma, E., S. Fournier, M. Poisson, R. Morisset, D. Phaneuf, and C. Vega. 1989. Clindamycin with primaquine for Pneumocystis carinii pneumonia. Lancet i:1046-1048.
46. Trepanier, L. A., K. Ray, N. J. Winand, S. P. Spielberg, and A. E. Cribb. 1997. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem. Pharmacol. 54:73-80.
47. Vennerstrom, J. L., and J. W. Eaton. 1988. Oxidants, oxidant drugs, and malaria. J. Med. Chem. 31:1269-1277.
48. Walsh, D. S., P. Wilairatana, D. B. Tang, D. G. Heppner, Jr., T. G. Brewer, S. Krudsood, U. Silachamroon, W. Phumratanaprapin, D. Siriyanonda, and S. Looareesuwan. 2004. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin. Infect. Dis. 39:1095-1103.
49. Wasunna, M. K., J. R. Rashid, J. Mbui, G. Kirigi, D. Kinoti, H. Lodenyo, J. M. Felton, A. J. Sabin, and J. Horton. 2005. A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya. Am. J. Trop. Med. Hyg. 73:871-876.